Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD to Launch Oral Rotavirus Vaccine RotaTeq on July 20
July 18, 2012
- Janssen Applies for HIV Drug Prezista Naive Tablet 800 mg
July 17, 2012
- Otsuka HD’s Vice Chairman Otake Resigns for “Personal Reasons”
July 17, 2012
- Bioventure Industry Caught in Negative Spiral: DBJ Report
July 17, 2012
- Cumulative Sales of Japan’s 1st Emergency Contraceptive NorLevo Nears 50,000 Packs in 1 Year
July 16, 2012
- RIJ Plans World’s First Trial of iPS Cell Therapy in Men: President & CEO Kagimoto
July 16, 2012
- Shionogi Announces Positive Results of Second PIII Study for Dolutegravir
July 13, 2012
- Daiichi Sankyo to Receive METI’s Grant for Its Biopharmaceutical Production Facility Expansion
July 13, 2012
- Astellas to Develop Companion Diagnostic Agents in Collaboration with Other Companies: President Hatanaka
July 13, 2012
- Yoshindo to Develop Biopharmaceutical Business in 3 Steps: President Shimomura
July 13, 2012
- Taiho, Teikoku Form Alliance for Cancer Pain Reliever
July 12, 2012
- Teijin Pharma to Boost New Drug Ratio to More than 50%, Prepare “Post-Feburic” Products: President Arao
July 12, 2012
- Micro Marketing Method to Be Potentially Effective in Future: Ninomiya of Novartis Pharma
July 12, 2012
- Bayer HealthCare Initiates Multinational PIII Trial for Hemophilia A Treatment BAY94-9027
July 12, 2012
- Nippon Chemiphar Aiming to Boost Generic Drug Sales to 30 Billion Yen in FY2014: President Yamaguchi
July 12, 2012
- Shionogi Files Lawsuit against InterMune of US over Royalties Payment
July 12, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Halaven Fails to Meet Primary Endpoints vs Capecitabine in PIII Study: Eisai
July 11, 2012
- Suzuken to Offer Voluntary Early Retirement Program for Record 500 Employees
July 11, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…